The FDA approved Yesafili and Opuviz as the first interchangeable biosimilars to Eylea, according to a press release from the FDA.
Yesafili (aflibercept-jbvf, Biocon Biologics) and Opuviz (aflibercept-yszy, Samsung Bioepis) are intended to treat neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion, diabetic macular edema and diabetic retinopathy as a 2 mg intravitreal injection.
“Yesafili will offer ophthalmologists an important new option for patients impacted by macular degeneration and diabetic retinopathy, from a company with a long history